These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8345004)

  • 1. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications.
    Gómez Bellver MJ; García Sánchez MJ; Alonso González AC; Santos Buelga D; Domínguez-Gil A
    J Clin Pharm Ther; 1993 Jun; 18(3):191-7. PubMed ID: 8345004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.
    Yu HY
    Ther Drug Monit; 1984; 6(4):414-23. PubMed ID: 6440321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose on the kinetic behaviour of valproic acid: modifications in plasma protein binding.
    Gomez MJ; Santos Buelga D; Alonso AC; Garcia MJ; Dominguez-Gil A
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():239-42. PubMed ID: 1820886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the serum protein binding of valproic acid limit the hepatic elimination?
    Kodama Y; Kuranari M; Teraoka I; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):529-32. PubMed ID: 8294164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy.
    Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yamaguchi T; Fujimura A
    Am J Health Syst Pharm; 2002 May; 59(9):835-40. PubMed ID: 12004461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of unbound clearance on binding parameters of valproic acid to serum proteins.
    Kodama Y; Tsutsumi K; Teraoka I; Fujii I; Takeyama M
    J Clin Pharmacol; 1993 Feb; 33(2):130-5. PubMed ID: 8440760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy.
    Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Fujimura A
    J Clin Pharmacol; 1999 Oct; 39(10):1070-6. PubMed ID: 10516942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of free fatty acids on valproic acid plasma protein binding during fasting in normal humans.
    Bowdle TA; Patel IH; Levy RH; Wilensky AJ
    Eur J Clin Pharmacol; 1982 Oct; 23(4):343-7. PubMed ID: 6816619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid dosage and plasma protein binding and clearance.
    Bowdle AT; Patel IH; Levy RH; Wilensky AJ
    Clin Pharmacol Ther; 1980 Oct; 28(4):486-92. PubMed ID: 6773716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo plasma protein binding interaction between valproic acid and naproxen.
    Grimaldi R; Lecchini S; Crema F; Perucca E
    Eur J Drug Metab Pharmacokinet; 1984; 9(4):359-63. PubMed ID: 6442704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent inhibition in plasma protein binding of valproic acid during continued treatment in guinea-pigs.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 1992 May; 44(5):408-12. PubMed ID: 1359055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid and diazepam interaction in vivo.
    Dhillon S; Richens A
    Br J Clin Pharmacol; 1982 Apr; 13(4):553-60. PubMed ID: 6802161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma protein binding interaction between phenytoin and valproic acid in vitro.
    Monks A; Boobis S; Wadsworth J; Richens A
    Br J Clin Pharmacol; 1978 Dec; 6(6):487-92. PubMed ID: 365209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding parameters of valproic acid to serum protein in healthy adults at steady state.
    Kodama Y; Koike Y; Kimoto H; Yasunaga F; Takeyama M; Teraoka I; Fujii I
    Ther Drug Monit; 1992 Feb; 14(1):55-60. PubMed ID: 1546390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients.
    Monks A; Richens A
    Clin Pharmacol Ther; 1980 Jan; 27(1):89-95. PubMed ID: 6985856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data.
    Sriboonruang T; Panomvana D; Chamchitchun S; Silpakit O
    J Clin Psychopharmacol; 2011 Feb; 31(1):115-9. PubMed ID: 21192154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats.
    Yu HY; Shen YZ; Sugiyama Y; Hanano M
    Drug Metab Dispos; 1990; 18(1):121-6. PubMed ID: 1970771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys.
    Viswanathan CT; Levy RH
    J Pharm Sci; 1981 Nov; 70(11):1279-81. PubMed ID: 6795339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-effect relationships of valproic acid.
    Chadwick DW
    Clin Pharmacokinet; 1985; 10(2):155-63. PubMed ID: 3922659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.
    Semmes RL; Shen DD
    Pharm Res; 1990 May; 7(5):461-7. PubMed ID: 2114617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.